Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 29:2021:7316456.
doi: 10.1155/2021/7316456. eCollection 2021.

HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies

Affiliations
Review

HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies

Tingxia Lv et al. J Immunol Res. .

Abstract

Although antiretroviral therapy effectively controls human immunodeficiency virus (HIV) replication, a residual chronic immune activation/inflammation persists throughout the disease. This aberrant immune activation and inflammation are considered an accelerator of non-AIDS-related events and one of the driving forces of CD4+ T cell depletion. Unfortunately, HIV-associated immune activation is driven by various factors, while the mechanism of excessive inflammation has not been formally clarified. To date, several clinical interventions or treatment candidates undergoing clinical trials have been proposed to combat this systemic immune activation/inflammation. However, these strategies revealed limited results, or their nonspecific anti-inflammatory properties are similar to previous interventions. Here, we reviewed recent learnings of immune activation and persisting inflammation associated with HIV infection, as well as the current directions to overcome it. Of note, a more profound understanding of the specific mechanisms for aberrant inflammation is still imperative for identifying an effective clinical intervention strategy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this paper.

Similar articles

Cited by

References

    1. Deeks S. G., Lewin S. R., Havlir D. V. The end of AIDS: HIV infection as a chronic disease. The Lancet . 2013;382(9903):1525–1533. doi: 10.1016/S0140-6736(13)61809-7. - DOI - PMC - PubMed
    1. Rodger A. J., Lodwick R., Schechter M., et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS . 2013;27(6):973–979. doi: 10.1097/QAD.0b013e32835cae9c. - DOI - PubMed
    1. So-Armah K. A., Tate J. P., Chang C. H., et al. Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people? Journal of Acquired Immune Deficiency Syndromes . 2016;72(2):206–213. doi: 10.1097/QAI.0000000000000954. - DOI - PMC - PubMed
    1. Kamat A., Misra V., Cassol E., et al. A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy. PLoS One . 2012;7(2, article e30881) doi: 10.1371/journal.pone.0030881. - DOI - PMC - PubMed
    1. Brenchley J. M., Price D. A., Schacker T. W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine . 2006;12(12):1365–1371. doi: 10.1038/nm1511. - DOI - PubMed

MeSH terms